GV-backed cancer drug developer Kronos Bio floated above its range in an upsized offering and saw its shares soar in price post-IPO.

US-based oncology drug developer Kronos Bio went public in a $250m initial public offering on the Nasdaq Global Select Market on Friday, providing an exit for internet and technology conglomerate Alphabet. The size of the offering was increased from almost 10.3 million shares to more than 13.1 million and they were priced at $19.00 each,…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.